Breaking News

Samsung, Kurma Partner on Biologics for Kurma’s Portfolio Companies

Samsung will provide customizable CMC development services for Kurma Partners.

Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, have entered into a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies. Under the multi-year agreement, Samsung Biologics will provide customizable chemistry, manufacturing, and control (CMC) development services for Kurma Partners’ portfolio compani...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters